Atezolizumab targets and inhibits the PD-L1 protein found on the surface of cancer cells. Normally, PD-L1 binds to PD-1 receptors on T-cells, deactivating them and allowing the cancer cells to evade immune response. By blocking this interaction, atezolizumab reactivates T-cells, enabling them to attack cancer cells.
